Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non ‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)

ConclusionsPatients who receive immune ‐checkpoint inhibitors as part of their treatment for NSCLC have better overall survival (OS) compared with matched patients treated with standard chemotherapy, regardless of the line of treatment.

Source: Thoracic Cancer - December 11, 2019 Category: Cancer & Oncology Authors: Alejandro Ruiz ‐Patiño, Oscar Arrieta, Andrés F. Cardona, Claudio Martín, Luis E. Raez, Zyanya L. Zatarain‐Barrón, Feliciano Barrón, Luisa Ricaurte, María A. Bravo‐Garzón, Luis Mas, Luis Corrales, Leonardo Rojas, Lorena Lupinacci, Tags: ORIGINAL ARTICLE Source Type: research